SCHEMBL421992

SCHEMBL421992

CCC(OC(CC)S(=O)(=O)O)S(=O)(=O)O

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.35
RECQL P46063 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2231703 0.97 TSHR (0.33) TSHR
SCHEMBL4731263 0.97 TSHR (0.33) TSHR
Glycerin SCHEMBL3242944 0.87 LMNA (0.38) TSHR
SCHEMBL11348448 0.85
SCHEMBL933651 0.82
SCHEMBL9290679 0.81
SCHEMBL37544 0.79 HDAC1 (0.39) TSHRRECQL
SCHEMBL9246019 0.79
SCHEMBL6384916 0.79 CA2 (0.30)
Hydrochloric Acid SCHEMBL5066545 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 412 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235121-A1 TIRAPAZAMINE COMPOSITIONS AND METHODS Teclison, Inc. (US) 2025-11-13 WO claimed
US-20250345356-A1 TIRAPAZAMINE COMPOSITIONS AND METHODS Teclison, Inc. (US) 2025-11-13 US claimed
CN-115317439-A Keliboro microneedle patch and preparation method thereof 合肥博思科创医药科技有限公司 2022-11-11 CN claimed
US-20210212321-A1 STABILIZED FUNGICIDAL COMPOSITION COMPRISING CYCLODEXTRIN BAYER CROPSCIENCE LP 2021-07-15 US claimed
EP-2152078-B1 FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE CYDEX PHARMACEUTICALS INC (US) 2021-01-13 EP claimed
CN-104800210-B Preparation comprising clopidogrel and sulfoalkyl ether cyclodextrin and its application method 锡德克斯药物公司 2019-08-06 CN claimed
EP-1732512-B1 INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID CYDEX PHARMACEUTICALS INC (US) 2017-03-22 EP claimed
EP-1594434-B1 PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS YEDA RES & DEV (IL) 2016-09-07 EP claimed
US-20160010086-A1 OLIGOMERIC COMPOUNDS AND EXCIPIENTS ISIS PHARMACEUTICALS, INC. (US) 2016-01-14 US claimed
CN-104800210-A Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use CYDEX PHARMACEUTICALS INC 2015-07-29 CN claimed
EP-1409592-B1 WATER-BASED COLORANT PREPARATIONS CLARIANT GMBH (DE) 2005-09-14 EP claimed
US-20050008634-A1 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2005-01-13 US claimed
US-6811673-B2 ZINC, OR ALLOY THEREOF, MATTE FINISHING; AUTOMOBILE PROTECTIVE COATING BASF AKTIENGESELLSCHAFT (DE) 2004-11-02 US claimed
US-20040206271-A1 Water-based colorant preparations CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) 2004-10-21 US claimed
US-20040180059-A1 Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus YEDA RESEARCH AND DEVELOPMENT CO. (IL) 2004-09-16 US claimed
WO-2004064788-A2 PARENTERAL FORMULATIONS OF A PEPTIDE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2004-08-05 WO claimed
WO-2004064787-A2 PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2004-08-05 WO claimed
EP-1409592-A1 WATER-BASED COLORANT PREPARATIONS Clariant GmbH (DE) 2004-04-21 EP claimed
WO-2003008503-A1 WATER-BASED COLORANT PREPARATIONS CLARIANT GMBH (DE) 2003-01-30 WO claimed
US-20010034333-A1 Cyclodextrin polymer compositions for use as drug carriers KOSAK KENNETH M (US) 2001-10-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034333-A1 Cyclodextrin polymer compositions for use as drug carriers ABCB1, ABCG2, CTTN TSHR 4603/4885RECQL 1905/4885
US-20210212321-A1 STABILIZED FUNGICIDAL COMPOSITION COMPRISING CYCLODEXTRIN CYP3A43, POR, CBR3 TSHR 4025/4885RECQL 2331/4885
US-20160010086-A1 OLIGOMERIC COMPOUNDS AND EXCIPIENTS HNRNPA3, SNRPE, HNRNPA1 TSHR 4274/4885RECQL 722/4885
US-20250345356-A1 TIRAPAZAMINE COMPOSITIONS AND METHODS TYMP, ROR1, CSNK1A1 TSHR 1442/4885RECQL 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.